STAT3 Inhibition to Treat Ulcerative Colitis-Associated Colorectal Cancer
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262110808 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Prema Robinson und 10 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Infectious Diseases, Infection Control & Employee Health, Division of Internal Medicine, The University of Texas MD Anderson Cancer Ce…. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Colitis, Ulcerative, Colorectal Neoplasms, Colitis-Associated Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NIH.
Abstract (Originalsprache)
In patients with inflammatory bowel disease (IBD), colorectal cancer (CRC) occurs with 20-to-30-fold higher frequency, is more advanced at diagnosis, and has a worse prognosis than in the general population. To improve their treatment options, we determined if targeting STAT3 with TTI-101, a small-molecule STAT3 inhibitor, was beneficial in the azoxymethane (AOM)-disodium sulfate (DSS) mouse model of colitis-associated CRC. C57BL/6 mice received a single intraperitoneal injection of AOM followed by three cycles of 5% DSS in drinking water before receiving TTI-101 (50 mg/kg by oral gavage, OG, and daily) or vehicle for 28 days. TTI-101 treatment reduced adenoma numbers by 89% from 1.14 ± 1.07 in vehicle-treated mice to 0.13 ± 0.35 in TTI-101-treated mice (p ≤ 0.05, Kruskal–Wallis test). Levels of activated STAT3 (pY-STAT3) were increased 3.3-fold in the epithelium and stroma of dysplastic mucosa (147 ± 46; mean ± SD; and n = 4) vs. normal mucosa (45 ± 26; n = 7; and p ≤ 0.05, Kruskal–Wallis test) and were correlated with the adenoma number. TTI-101 was detected at pharmacologically relevant levels in the plasma and colons of TTI-101-treated AOM-DSS mice and was concentrated within colon tissue; plasma TTI-101 levels inversely correlated to pY-STAT3 levels. Importantly, TTI-101 normalized the colon transcriptome of AOM-DSS mice and reduced the expression of STAT3- and STAT1-upregulated genes associated with CRC oncogenesis. Thus, TTI-101 treatment may benefit IBD patients with CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Infectious Diseases, Infection Control & Employee Health, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.
- Department of Symptom Research Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.
- Department of Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.
ORCID-Profile: Zal Italia, Zara Italia, Tan Hoang, Leticia Hamana Zorrilla, Luisa Maren Solis Soto, David J Tweardy
Förderung
- NCI NIH HHS
- NIH HHS
- NIH
Zitieren
APA
Robinson, P., Italia, Z., Italia, Z., Hoang, T., Rodriguez, E., Eckols, T. K., Kasembeli, M., Zorrilla, L. H., Soto, L. M. S., Mahalingam, R., & Tweardy, D. J. (2025). STAT3 Inhibition to Treat Ulcerative Colitis-Associated Colorectal Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262110808
Vancouver
Robinson P, Italia Z, Italia Z, Hoang T, Rodriguez E, Eckols TK, et al. STAT3 Inhibition to Treat Ulcerative Colitis-Associated Colorectal Cancer. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262110808
BibTeX
@article{Robinson2025,
author = {Robinson, Prema and Italia, Zal and Italia, Zara and Hoang, Tan and Rodriguez, Emma and Eckols, T Kris and Kasembeli, Moses and Zorrilla, Leticia Hamana and Soto, Luisa Maren Solis and Mahalingam, Rajasekaran and Tweardy, David J},
title = {STAT3 Inhibition to Treat Ulcerative Colitis-Associated Colorectal Cancer},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262110808}
}
EUVIMED